ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

ClinicalTrials.gov ID: NCT01478321

Public ClinicalTrials.gov record NCT01478321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas

Study identification

NCT ID
NCT01478321
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Northwestern University
Other
Enrollment
54 participants

Conditions and interventions

Interventions

  • Temozolomide Drug
  • bevacizumab Biological
  • hypofractionated radiation therapy Radiation
  • questionnaire administration Other

Drug · Biological · Radiation + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2011
Primary completion
Sep 11, 2018
Completion
Sep 11, 2018
Last update posted
Mar 11, 2020

2011 – 2018

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
4
Facility City State ZIP Site status
Northwestern University Chicago Illinois 60611
University of Chicago Chicago Illinois 60637
Northwestern Lake Forest Hospital Lake Forest Illinois 60045
Edward Cancer Center Naperville Illinois 60540
Central Dupage Hospital Warrenville Illinois 60555

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01478321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 11, 2020 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01478321 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →